ReviewCureus2026
Molecular Determinants of Osseointegration in Implant-Supported Prostheses: A Narrative Review of Gene Expression Signatures, Signaling Pathways, and Bioinformatic Insights.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osseointegration is a biologically complex process that determines the long-term success of implant-supported prostheses. Advances in molecular biology have shown that gene expression programs and signaling networks, rather than mechanical fixation alone, govern bone healing and implant integration. Yet, these molecular determinants are still seldom used to guide clinical decisions, which continue to rely on mechanical and histologic assessments. This narrative review addresses that gap by analyzing the molecular determinants of osseointegration through five connected perspectives: the cellular cascade that follows implant placement; the principal osteogenic signaling pathways (bone morphogenetic protein (BMP), Wnt/β-catenin, nuclear factor kappa B (NF-κB), and Runt-related transcription factor 2 (RUNX2)); transcriptomic signatures across the inflammatory, repair, and remodeling phases; bioinformatic gene regulatory and protein-protein interaction networks associated with implant success or failure; and the influence of implant surface properties on the molecular response. Across these perspectives, osteogenic and angiogenic genes such as RUNX2, collagen type I alpha 1 chain (COL1A1), bone gamma-carboxyglutamate protein (BGLAP), and vascular endothelial growth factor A (VEGFA) are consistently linked to successful integration, whereas sustained inflammatory and osteoclastogenic signatures such as IL6, tumor necrosis factor (TNF), matrix metalloproteinase-9 (MMP9), and nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (NFKB1) characterize failure. The review then considers how this knowledge may be translated into gene expression-based biomarkers, peri-implant crevicular fluid monitoring, patient risk stratification, and precision implant therapy, and identifies the main barriers to clinical adoption of an emerging implantogenomics framework.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.